comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists The effects of receptor beyond obesity type 2 diabetes: An anti-atherosclerotic action A comparison of the effects
Description
Gagne-Ouellet V, Breton E, Thibeault K, Fortin CA, Cardenas A, Guerin R, et al
00032-X/asset/f312f4e3-50d1-472f-90c9-896e4cef8e23/main.assets/gr1_lrg.jpg)
Investigational medicines are not approved unless specifically stated by regulators
This is important because GLP-1 drugs were originally designed to have a long half-life in blood to maximise their efficacy in the treatment of diabetes which prevents them from entering the brain (Hlscher)
Approved by the FDA in 2022 for type 2 diabetes, tirzepatide has demonstrated superior glycemic control and significant weight loss
Goodman did a BSc degree in chemistry and then an MD and PhD at Penn University
